Full-Time
Senior Director
Portfolio Reporting & Analytics
Dyne Therapeutics
201-500 employees
Develops muscle-disease therapies using FORCE platform
Compensation Overview
$233k - $285k/yr
Waltham, MA, USA
In Person
Bachelor's, Master's, MBA, PhD
 Data & Analytics (2) |
|---|
| , |
Get referred to Dyne Therapeutics
See people who can refer or advise you
- A bachelor's degree in a quantitative or life sciences field, such as Statistics, Data Science, Engineering, Operations Research, Epidemiology, Pharmacy, or Biology.
- Fifteen or more years of increasing responsibility in biopharma or biotech research and development, focused on clinical operations analytics, portfolio management, or development operations, including five or more years leading multidisciplinary teams.
- A proven track record building enterprise data and analytics platforms and single-source-of-truth solutions for research and development portfolios, integrating internal and external or vendor data such as contract research organization feeds and benchmarks.
- Demonstrated expertise with portfolio, program, and study key performance indicators; operational planning and planned-versus-actual analysis; and scenario modeling for timelines, costs, risks, and resources.
- Hands-on experience with advanced analytics and machine learning, including forecasting, simulation, and optimization, and turning algorithms into operational tools that drive business decisions.
- A strong understanding of the clinical development lifecycle, including feasibility, site activation, enrollment, data management, monitoring, and close-out; and familiarity with Good Clinical Practice, GxP, data privacy, and validation expectations for decision-support tools.
- Executive presence and the ability to influence senior stakeholders, translate complex analytics into clear narratives, and drive enterprise alignment.
- The ability to influence without direct authority across all organizational levels, including senior functional leaders.
- The ability to convey complex information clearly to diverse audiences in written, verbal, and presentation formats.
- The ability to interpret and communicate complex data to diverse audiences.
- The ability to work in a matrix environment.
- The ability to work independently as a hands-on manager and proactively contribute as a resource when necessary.
- Flexibility to adapt and meet changing customer needs.
- A high level of integrity, compliance, ethics, and transparency.
- Design, define, and advance a next-generation clinical and portfolio insights platform that delivers trusted, real-time reporting and analytics across studies, programs, and the portfolio, enabling monitoring of time, cost, and quality and supporting decision-making from study teams to the Executive Committee and Board.
- Establish and govern one source of truth by integrating internal and external operational data, including contract research organization and vendor feeds and benchmarking sources, into a harmonized model with robust data quality, lineage, and access controls.
- In partnership with Information Technology and Digital, architect centralized operational data infrastructure, such as a data lake or warehouse, semantic layer, and data products, that powers consistent analytics and self-service business intelligence.
- Integrate operational planning data, including study and program plans, budgets, and baselines, with actuals to enable accurate planned-versus-actual comparisons for timelines and costs.
- Implement scalable operational data governance covering metadata, master data, and standards aligned with research and development operating models and GxP expectations.
- Develop standardized analytical frameworks and methodologies, including definitions, metric specifications, and visualization standards, to drive consistency and comparability across the organization.
- Define and operationalize clinical study, program, and portfolio key performance indicators and performance analytics, including cycle times, site activation and enrollment velocity, budget adherence, deviation and quality indicators, vendor performance, and milestone attainment.
- Lead the creation of advanced analytics and simulation capabilities to predict and optimize development timelines, costs, and risks, including slippage forecasting, patient enrollment trajectories, budget risks, and operational risks.
- Design and deploy prescriptive analytics powered by artificial intelligence and machine learning that anticipate study, program, and portfolio-level challenges and provide actionable recommendations such as mitigation strategies, scenario trade-offs, risk flags, and next-best actions.
- Enable portfolio-wide scenario modeling and resource planning to support governance decisions involving starting, stopping, sequencing, trade-offs, capacity constraints, and resource supply.
- Develop predictive country and site selection analytics to optimize trial delivery and inform feasibility and country footprint decisions.
- Establish a study-level insights platform using structured operational data to provide site- and principal-investigator-level insights on enrollment health, quality, cost, and competitive trial density to study teams and vendor partners.
- Design and institutionalize an integrated resource management capability that analyzes resource demand versus actuals across the portfolio, predicts artificial-intelligence-enabled resource demand, and highlights capacity bottlenecks for scarce skills and roles in partnership with Human Resources and functional leaders.
- Drive change management and adoption of new analytics capabilities, embedding insights in governance reviews, quarterly business reviews, portfolio prioritization, and study health checks.
- A master's degree or PhD in Data Science, Biostatistics, Operations Research, or a related discipline.
- An MBA.
- Experience with site and country selection analytics, enrollment prediction, and vendor performance analytics.
- Familiarity with research and development systems such as clinical trial management systems, electronic data capture, electronic trial master file, randomization and trial supply management, safety, and electronic clinical outcome assessment systems; portfolio and financial planning tools; and human resources capacity planning.
- A background in data governance, including metadata and master data management, data product management, and adoption at scale.
Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2017
Get referred to Dyne Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA accepted z-rostudirsen's BLA on July 20, 2026, with January 21, 2027 PDUFA.
- Dyne ended Q2 2026 with $898.5 million cash and Q2 2028 runway.
- ACHIEVE finished 71-patient enrollment on June 3, 2026; HARMONIA already started.
What critics are saying
- Dyne burned $178.6 million in Q2 2026, pressuring execution before commercialization.
- Sarepta's Exondys 51 already entrenches exon-51 prescribers before Dyne's January 2027 review.
- A rejected z-rostudirsen BLA would strand Dyne's launch plan and trigger fatal financing stress.
What makes Dyne Therapeutics unique
- Dyne's FORCE platform targets TfR1 muscle delivery, differentiating from standard exon-skippers.
- Z-rostudirsen produced 5.46% dystrophin at six months in DELIVER's registrational cohort.
- Z-basivarsen and z-rostudirsen share one delivery platform across DMD and DM1.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↓ -2%2 year growth
↓ -3%Dyne Therapeutics has commenced an underwritten public offering of $300 million of its common stock. The clinical-stage company, which focuses on treatments for genetically driven neuromuscular diseases, also plans to grant underwriters a 30-day option to purchase up to an additional $45 million of shares. Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also serving as joint book-running managers, whilst Jones is acting as lead manager. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on 5 March 2024. The company is currently developing clinical programmes for myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect 'smooth' review. July 21, 2026 | If approved, Dyne Therapeutics' zeleciment rostudirsen could "capture the majority" of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Therapeutics' exon-skipping therapy Exondys 51, the current standard of care, according to Oppenheimer. The FDA has accepted Dyne Therapeutics' application for its investigational Duchenne muscular dystrophy therapy, setting a target action date of Jan. 21, 2027. "We anticipate a smooth approval," Oppenheimer told investors in a note on Monday, adding that the therapy, dubbed zeleciment rostudirsen (z-rostudirsen) is poised to "capture the majority of market share," given stronger dystrophin benefits and a more convenient dosing profile than the current standard treatment. Outside of symptomatic management through corticosteroids, Sarepta Therapeutics' Exondys 51 is a standard of care regimen for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Dyne, however, could challenge Exondys with z-rostudirsen, which in the Phase 1/2 DELIVER trial outperformed Sarepta's asset, Jefferies said in a Monday note, adding that the early data cut looks "best-in-class." Exondys is dosed weekly, while z-rostudirsen is designed to be given once every four weeks - a "convenient" profile, the firm noted. Given its convenience and efficacy advantages, "z-rostudirsen could command a pricing premium" if approved, Jefferies continued. The analysts added that they expect uptake to be "robust" across three key patient subgroups: those who have yet to undergo Exondys treatment, those who have discontinued Sarepta's therapy and those who are currently receiving it. Dyne is seeking accelerated approval for z-rostudirsen in patients with DMD who are amenable to exon 51 skipping, according to a company release on Monday. Topline data from the registrational cohort of DELIVER, released December 2025, showed a 5.46% increase at six months in concentrations of the dystrophin protein, a key disease marker. Patients also saw improvements in key functional measures, including time-to-rise velocity and the 10-meter walk/run test. Lung function, a major driver of death in DMD, was preserved at six months. Dyne's exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the "best ever" for this treatment class, Stifel analysts said. December 8, 2025 The FDA does not plan on holding an advisory committee meeting for z-rostudirsen, according to Dyne. Jefferies models more than $500 million in peak sales for z-rostudirsen, calling this estimate "conservative." Oppenheimer, on the other hand, did not provide a peak forecast for the z-rostudirsen, only noting that Dyne's therapy could secure a "majority" of the $1.5 billion exon-51 DMD market. In DMD, a rare and progressive neuromuscular disorder, mutations to the dystrophin protein render it dysfunctional or completely absent. Under healthy conditions, dystrophin plays a crucial role in maintaining the structure and function of muscles. Z-rostudirsen works by restoring the expression of near-full-length dystrophin, in turn restoring the function of the protein. A key player in the DMD space is Sarepta, which aside from Exondys owns the gene therapy Elevidys. Last year, two patients died after receiving Elevidys, which ultimately forced the FDA to slap a boxed warning on the product's label and limited its use to ambulatory patients four years and up. Sarepta also owns Amondys 45 and Vyondys 53 - both exon-skipping drugs like Exondys - which in November 2025 failed to elicit significant motor function improvements in the confirmatory Phase 3 ESSENCE study. Sarepta has nevertheless pushed for full approval of these products, with the FDA setting a decision date of Feb. 28, 2027. Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs' failure to improve motor function in a confirmatory trial. July 1, 2026
Dyne Therapeutics announces a $300 million public offering of common stock to support its neuromuscular disease programs.Quiver AI SummaryDyne Therapeutics, Inc. has announced the commencement of an underwritten public offering of $300 million in shares of its common stock, with a potential additional sale of $45 million if underwriters exercise their option. The shares will be sold by Dyne, and the offering is being managed by Morgan Stanley, Je
Dyne Therapeutics completes $230 million public offering of 27.8 million shares to advance neuromuscular disease therapies. |
Dyne Therapeutics vs. Vertex Pharmaceuticals: which drug innovator stock is a better buy in 2026? Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare? Key points. * Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform. * Vertex Pharmaceuticals maintains a dominant market share in cystic fibrosis while expanding its reach into gene editing and pain management. * Which of these biotechnology players offers a more compelling risk-to-reward profile for your portfolio? * Motley Fool Issues Rare "Total Conviction" Buy Alert" Choosing between a high-growth clinical-stage player and an established industry titan can be difficult for investors. This comparison examines Dyne Therapeutics (DYN 1.15%) and Vertex Pharmaceuticals (VRTX +0.22%) to help you determine the better buy. DYN & VRTX: performance comparison. DYN (Dyne Therapeutics) VRTX (Vertex Pharmaceuticals) Key financial metrics. DYN - Dyne Therapeutics - 1.15 % (- $ 0.26) VRTX - Vertex Pharmaceuticals + 0.22 % (+ $ 1.09) Market Cap 52wk Range $ 8.06 - $ 25.00 Market Cap 52wk Range $ 362.50 - $ 507.92 Gross Margin Dyne focuses on delivering targeted nucleic acid medicines to muscle tissue using its proprietary delivery platform. Vertex is the global leader in cystic fibrosis treatment and is now diversifying its pipeline into new areas like acute pain and sickle cell disease. Both companies operate in the high-stakes world of biotechnology but represent different levels of corporate maturity. The case for Dyne Therapeutics. Dyne Therapeutics is a clinical-stage company among biotech stocks that aims to treat rare, genetically driven diseases through its proprietary FORCE platform. It is currently developing therapies for conditions like Duchenne muscular dystrophy and myotonic dystrophy type 1, which have high unmet medical needs. Because the company is still in the development phase, it currently has no commercial customers and relies on external capital to fund its research. In FY 2025, Dyne had no revenue because the company is still testing its lead drug candidates and has no products on the market. This lack of sales resulted in a net loss of $446.2 million for the year. This loss was wider than the $317.4 million net loss reported in the prior fiscal year, largely due to higher clinical trial and laboratory costs. The current debt-to-equity ratio stands at approximately 0.2x. A current ratio measures a company's ability to pay short-term obligations, indicating its liquidity strength to fund future trials. Free cash flow was negative at approximately $405.1 million in FY 2025. The case for Vertex Pharmaceuticals. Vertex Pharmaceuticals is a powerhouse in the medical sector, known for its dominant position in cystic fibrosis treatments. Its product portfolio includes blockbuster drugs that are distributed primarily through a limited number of specialty pharmacies and wholesalers. Beyond its core niche, the company is actively diversifying into new therapeutic areas, such as acute pain and type 1 diabetes, to ensure long-term growth. In FY 2025, revenue reached $12 billion, representing a year-over-year increase of nearly 10%. The company reported net income of nearly $4 billion, resulting in a net margin of approximately 32.7%. Net margin indicates how much of every dollar in revenue actually becomes profit after all expenses, and the company's P/S ratio, which compares its stock price to its total sales, reflects its market standing. Its current debt-to-equity ratio is approximately 0.1x. This ratio compares total debt to shareholder equity, and a lower number indicates a conservative approach to borrowing. Free cash flow for FY 2025 was close to $3.2 billion. Free cash flow is the cash a company generates after accounting for the money spent to maintain or expand its asset base. Risk profile comparison. Financial sustainability remains a primary concern for Dyne Therapeutics, given the company's history of significant operating losses. It depends on a loan agreement with Hercules Capital that includes strict financial covenants, which could restrict its operations if its cash reserves fall too low. Additionally, its drug candidates are in early clinical stages, which means there is a high risk of failure to demonstrate safety or efficacy during trials. Vertex Pharmaceuticals faces significant revenue concentration because its business is heavily dependent on its cystic fibrosis portfolio. Any safety issues or new competition from large peers such as AbbVie Inc. (ABBV 0.54%) could materially harm its financial results. The company also deals with global pricing pressures from government cost-containment efforts and ongoing intellectual property litigation involving ToolGen related to gene-editing technology. Valuation comparison. Vertex Pharmaceuticals trades at a premium reflecting its profitability, while Dyne Therapeutics has no sales or earnings expected in 2026 to base ratios on. | Metric | Dyne Therapeutics | Vertex Pharmaceuticals | Sector Benchmark | | Forward P/E | n/a | 26x | 24.8x | | P/S ratio | n/a | 10.3x | / | Sector benchmark uses the SPDR XLV sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers. Which stock would I buy in 2026? These are two companies at different stages of their pharmaceutical life. Where to invest $1,000 right now. When its analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 902% - a market-crushing outperformance compared to 209% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now... *Stock Advisor returns as of June 29, 2026 Dyne Therapeutics may not have revenue, but its $3.7 billion market cap is a sign of investors' faith in the business. Dyne is preparing its first product for Duchenne Muscular Dystrophy to enter the market in the first quarter of fiscal 2027, with its second product, DM1, planned for a year later. Long-term revenue projections are inherently more speculative, but analysts see Dyne making $53 million in sales in 2027 and $277 million in 2028, and reaching well over $1 billion in 2030. That's a great outlook. Vertex, meanwhile, is building on its dominant position in cystic fibrosis treatment, investing heavily in research and development. In just a few years, Vertex has expanded its CF drug treatments so it now could treat 95% of all CF patients in the U.S. Approvals in other markets are coming through, which means the market for its existing drugs continues to expand. The company is also deep in trials for a drug to treat conditions that lead to renal failure, a new market for Vertex. The U.S. has accelerated approval for povetacicept in IgA nephropathy, a treatment that would be a blockbuster ($1 billion-plus in lifetime sales) if approved. Dyne is a very promising company that looks on track to generate revenue next year. But Vertex continues to be a fast grower, with Wall Street seeing sales grow more than $1 billion this year to over $13 billion, with nearly $4.5 billion net income. With an expanding market, heavy R&D, and a decent price-to-forward earnings ratio, Vertex gets the nod. Is Dyne Therapeutics a long-term buy right now? Before you buy stock in Dyne Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Dyne Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of its recommendation, you'd have $385,055!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of its recommendation, you'd have $1,228,089!* Now, it's worth noting Stock Advisor's total average return is 902% - a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of July 1, 2026.